GENFIT's Positive Phase 2 Results for Elafibranor in PSC Announced

On April 28, 2025, GENFIT revealed that Ipsen would present positive Phase 2 data on elafibranor for Primary Sclerosing Cholangitis (PSC) at the EASL Congress. Elafibranor showed significant efficacy, notably reducing alkaline phosphatase levels in the ELMWOOD trial. Patients taking 80 mg and 120 mg dosages experienced notable improvements as early as week 4 and stabilization of Enhanced Liver Fibrosis at week 12.

Elafibranor, known as Iqirvo®, is already marketed for Primary Biliary Cholangitis (PBC) and is noted for its favorable safety profile. The drug was developed by GENFIT and licensed to Ipsen. GENFIT continues to focus on liver diseases, believing in elafibranor's potential to address significant unmet needs.